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ABSTRACT
Heparinnas oeen snown to 5locK proliferation in vascular smooth muscle
cells which is an early event in the genesis of atherosclerotic plaques.. Heparin's
effects on vascular endothelial cells, however, indicate it may downregulate the
stress pathways that characterize the initial stages of heart disease. This study
tracks the activation of p38 and INK-I, intermediates in the signal transduction of
the stress response in endothelial cells. Results indicate heparin downregulates
the phosphorylation of p38, and its effect on INK-I is undetermined. These data
indicate heparin or its analogs may have uses in the treatment of heart disease.
VI
Introduction
The endothelial basis ofatherosclerosis
Atherosclerosis, better known simply as heart disease or "hardening of the
arteries", causes over half of all deaths in the United States, Europe, and Japan
(1,2,3). Hypercholesteremia, hypertension, nicotine use, diabetes and obesity
r'
aggravate the condition, and potentially lead to stroke, myocardial infarction, and
gangrene of the extremities (1,2,3). The disease is, however, a cumulative
process over the course of a lifetime and may begin as early as childhood (1).
The hallmark of atherosclerosis is the deposition of fatty plaques on the
inner surface of the artery wall in response to minor injury (1,2). The forces that
injure the endothelium at the cellular level may include fluid shear stress and the
tangential component of the hemodynamic force (4). Plaques result from the
excessive response of the normal wound repair pathways involving growth
factors and cytokines in endothelial cells. These response-to-injury pathways
cause cardiac arteries to slowly narrow, resulting in heart disease, myocardial
infarction, and eventually, death. Evidence in the literature implicates the signal
transduction pathways leading to the activation of stress activated protein kinases
(SAPKs) p38 and JNK-1 in this process in both endothelial and smooth muscle
cells (SMCs). These pathways affect the stress response of the cell to various
extracellular conditions instead of the mitogenic outcome that is the result of
activation of the better-studied mitogen-activated protein kinase (MAPK)
pathway. Activation of the SAPK pathway can take many forms, with cell
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stretching, ceramides, G-protein-coupled receptor agonists, chronic hypoxia,
ischemia/reperfusion, integrin clustering, and vasoactive peptides among them
(5). While the MAPK pathway may promote varied outcomes, like apoptosis,
proliferation, hypertrophy, repair, or growth in different tissues (6,7), we are
interested in the response ofvascular endothelial cells to stress through activation
of the SAPK pathway.
Heparin's role in treatment ofheart disease
Heparin, a negatively charged glycosaminoglycan well-known for its·
anticoagulant properties, has been shown to inhibit the growth and proliferation
of SMCs through specific, high-affinity binding sites. Heparin uptake occurs
through what appear to be both receptor-mediated and endocytotic pathways (8).
Heparin's mechanistic role in blocking or controlling SAPK pathways in
endothelial cells is the focus of this research. Other aspects of research currently
being conducted in our lab include purification of the heparin receptor in SMCs,
upregulation of heparan sulfate proteoglycans, and localization of MAPKs in
response to heparin treatment in SMCs.
While heparin itself, due t.o its side effects in long-term use, may not be
used in a clinical protocol to treat atherosclerosis, an understanding of the signal
transduction cascade that results from activation of the hep.arin receptor is
beneficial to the study of the excessive wound response that is the hallmark of
atherosclerosis. Although heparin's anti-proliferative qualities have proven
useful in animal studies of atherosclerosis and restenosis, human trials have been
2
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less successful. This is likely because heparin is sequestered by human blood
serum but not by fetal bovine serum, which is commonly used during in vitro,
cell culture, and animal studies (9). The use of heparin analogs instead during
human trials may result in a new clinical protocol for the treatment ofheart
---------------~--------'-------" "---" "----"
disease, as the heparin molecule's anticoagulant properties are separate and
distinct from its antimitotic qualities (10).
Endothelial injury marks the genesis offatty arterial plaques
In 1993, Russell Ross put forth the "response-to-injury" hypothesis to
explain the development of artery narrowing and blockage, suggesting that the
disease begins with an insult to the endothelial·cells which line the arteries. This
insult causes the endothelium, normally a permeability barrier and an
anticoagulant surface, to become dysfunctional. Endothelial changes occur, and
can be monitored by polymorphonuclear leukocyte recruitment (PMNs) and
expression of adhesion molecules like CAMs on the inner surface of the artery, as
well as the accumulation of low-density lipoproteins (LDLs) in the artery. In
high blood concentrations, LDLs quickly become oxidized (oxLDLs) and toxic to
the endothelial and smooth muscle cells of the affected vessel. oxLDLs cause the
secretion of chemoattractants and growth regulatory molecules, which recruit
monocytes and T lymphocytes to the site of injury (1,2)..
The innermost layer of the artery wall is known as the intima, and it is
here that the cells' stress pathway reaches its physiological endpoint. Lesions
called "fatty streaks" appear on the intima, and are formed from the aggregation
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oflipid-rich macrophages and T-cells (1,2). Macrophages are formed from
monocytes which migrate into the subendothelial space of the artery and become
transformed (1,2). These white blood cells then ingest the oxLDLs and become
foam cells. Foam cells characterize the appearance of the fatty streak, the most
----------~~----- ------------ ~~~~-
obvious precursor of heart disease on the inner surface of the artery (1,2).
Also contributing to the formation of an atherosclerotic plaque are
elements of extracellular matrix, including elastic fiber proteins, collagen,
proteoglycans, and other necrotic debris (1,3). Proteoglycans contain
glycosaminoglycan side chains, and the heparin molecule is structurally related to
the heparan sulfate component ofproteoglycans (10,11). These components are
synthesized in lower concentrations by smooth muscle cells whiGh have migrated
from the tunica media to the intima layer. Together, the accumulation of these
materials forms a fibrous plaque which may occlude the blood vessel (1,3).
Many molecules modulate the response of endothelial cells to
extracellular stimuli. Tumor necrosis factor (TNF-a), interleukin-1 (IL-1~), free
---\. .
oxygen radicals, transforming growth factor ~ (TGF-~), histamine, thrombin,
oxLDL, platelet-derived growth factor (PDGF), and platelet-activating factor
(PAF) provoke a procoagulant response (1,3,11). These factors are largely
derived from and secreted by smooth muscle cells, platelets, and macrophages (1,
2, 11, 12).
SAPK and MAPK pathways pass extracellular stimuli to the nucleus
The stress message moves from the cell surface inward through a series of
kinases, each of which is known by multiple names. The early steps of the
cascade are unclear, and may activate GTPases Racl and RhoA (13). Other
upstream regulators of MAPKs may exist which are directed in a cell-specific
manner, and result in different responses to similar extracellular stimuli through
differential gene expression (4). Later elements of the cascade, however, are
better characterized. One constituent of the MAPK pathway is ras, which helps
to activate raf, also known as MAP kinase kinase kinase (MAPKKK). The
MAPKKKs activate MAPKKs, including MKK, MEK, SEK, or JNKK in the
stress pathways, which then add a phosphate group to the protein JNK,;1 or p38,
which are MAPK analogs (14, 15) called stress-activated protein kinases
(SAPKs). The pathways leading to the activation ofp38 and JNK-1 have distinct
intermediates. For instance, JNK-1 is phosphorylated by MKK4 and MKK7 (15,
16). p38's pathway may include TAK1 as a MAP kinase kinase kinase candidate,
with specificity for MEK homologs MKK3, MKK4 and MKK6 as substrates
(reviewed in 17). JNK-1 and p38 translocate from the cytoplasm to the nucleus,
where they phosphorylate transcription factors such as jun which then alter
transcription (18, 19,20,21). Signal transduction through a sequential series of
. kinases in SAPK pathways allows the cell multiple opportunities for modulation
of the stress response, and the presence of different proteins in parallel cascades .
may alter the kinetics and magnitude ofMAPK response to stress (4).
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Heparin's effects on signal transduction in MAPK and SAPKpathways
Heparin is well-known for its anti-coagulant properties, and has been
shown to curtail the activation ofMAPKs in cultured smooth muscle cells, and
thereby their gro~~ _a~~l1:1i~ation. Less studied, ho~ev~~, are the mol~s~~~'_~
effects on the signal transduction of a stress message in endothelial cells. While
the molecule has been shown to consistently return endothelial cells to an
anticoagulant state, the specific portion of the pathway it modulates is unclear.
Heparin is a glycosaminoglycan consisting of repeating disaccharide sequences
ofD-glucuronic acid l,4-linked to N-acetyl-D-glucosamine. The molecule also
causes the production of excess tissue factor pathway inhibitor and tissue-type
plasminogen activator in endothelial cells. These substances promote
anticoagulant processes (22, 23). Heparin-treated endothelial cells express
heparan sulfate proteoglycans in a dose-dependent relationship (24,25,26,27).
The "wounded" cell layer causes the concentratiQn of the heparan sulfate
component to drop, decreasing the concentration of anti-mitotic heparin
molecules present in the intimal layer (28). Vascular uptake of LDLs is decreased ..-..
due to the negative charge these proteoglycans confer on the endothelium (26,
27).
Physiological responses to stress in endothelial cells
One of the physiological endpoints of the endothelial stress response is the
expression of adhesion molecules which contribute to the formation of the fibrous
plaque. Physiological responses to stress in endothelial cells may include the
6
formation of complexes to promote clotting and cell adhesion. Recently, it has
been suggested that activation of the SAPK pathway with cytokines causes an .
increase in transcription of genes coding for cell adhesion molecules in
conjunction with the clotting response (28, reviewed in 29). Some evidence
.. .. .... _. --- -- - _. - -- -- - - _._--_.- -------
suggests heparin has the ability to inhibit leukocyte recruitment to the
endothelium through the binding of L-selectins (30, 31). Endothelial cells quickly
express E-selectin after treatment with IL-l~, TNF-a, and lipopolysaccharide,
and these adhesion molecules also recruit leukocytes to the endothelial lesion
(28). Heparin has also been found to decrease expression of intercellular
adhesion molecules at the transcriptional level in endothelial cells (32).
The role ofp38 and JNK-l in atherosclerosis
The protein kinases p38 and JNK-l are MAPK analogs in cellular stress
pathways, which have been found to be sensitive to environmental stresses like
ultraviolet and x-ray radiation, hydrogen peroxide, protein synthesis inhibitors,
and osmotic and heat shock (19). p38 is analogous to a protein in the high
osmolarity glycerol response (HOGl) pathway in yeast which is responsive to
hyperosmolarity and osmotic imbalance. It has been localized to the nucleus of
the cell (33, 34). This suggests that p38 plays a role in signal mediation to the
nucleus, which is strongly supported by the fact that transcription factors like
ATF2, CREB, and CHOP are among the protein's substrates (35/~6, 37, 38).
,
Also, though p38 is weakly activated through the protein kinase C (PKC)
pathway, it is strongly activated by LPS and inflammatory cytokines such as
7
those used in our research like IL-I~ and TNF-a (37, 39). Evidence suggests that
p38 is linked to heart disease through its role in preconditioning's protection of
the artery, and its activation may spur the signal transduction cascade of ischemic
preconditioning (40). p38 phosphorylates MAPK-activated protein kinase-2, and
-"- -- -_ ..
plays a role in mediating apoptosis and cytokine production. This intracellular
kinase is a well-known mediator of both apoptosis and cell-cycle arrest, and is
itself phosphorylated by SAPKK-2.
c-Jun NHrterminal kinase (JNK-I) has many similarities to p38, in that it
also plays a role in apoptosis, and activates transcription factors like c-Jun, Elk-I,
and ATF2 after being translocated into the nucleus, upregulating their activity
(41,42). JNK-I is activated preferentially by cellular stress, and to a lesser
degree, inflammatory cytokines like TNF-a and IL-I~. JNK.:.I phosphorylates c-
jun at serines 63 and 73, and binds to the adjacent amino acid sequence within the
N-terminus of the transcription factor called the "delta region" (4). In addition,
the pathway which activates JNK-I is susceptible to crosstalk from other
signaling cascades. For instance, PKC negatively regulatesJNK through
increased expression of MAP kinase phosphatase-l (MKP-I). This MAPK is
requiredfor cellular processes in the early embryonic development ofDrosophila
and mammalian cells (17) and contributes to apoptotic and immune responses
and oncogenic transformation (4). The transformation experienced by endothelial
cells in response to altered patterns ofblood flow have been linked to the
activation of this SAPK (41)..
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JNK-l and p38 are both members of a dually-phosphorylated class of
kinases generally termed MAPKs. Phosphate groups are added in the motif Thr-
Xaa-Tyr, where Xaa is Pro in JNK-l and Gly in p38 (37,42,43). JNK-l and p38
are activated by mitogen-activated kinase kinases (MKKs); specifically, MKK3
and MKK6 activate p38, while MKK4 activates both proteins. p38 and JNK-l are
part ofparallel MAPK cascades activated in response to cellular stress. It has
been suggested for JNK-l in particular that the MAPK's action may promote cell
survival and repair (4). Evidence suggests that JNK-l and p38 playa role in the
dismantling of collagen in fibrous plaques through the induction ofmatrix
metalloproteinases like collagenases, stromelysin, and gelatinases (reviewed in
29).
Phosphatases help control the activation state o!SAPKs
Our lab has hypothesized that heparin or its analogs may be appropriate
for the prevention of heart disease as it blocks the excessive wound response of
the MAPK pathway in the endothelium and smooth muscle of artery walls. It is
clear that the phosphorylation state of the SAPKs in question is controlled by the
competing actions of upstream kinases and expressed MKPs. Two possible
mechanisms for heparin's action have been proposed. First, heparin may
inactivate p38 and JNK-l by ~pregulating a member of the MKP family. MKP-l
'is an immediate early gene product whose expression is induced by growth
factors (40), and has been shown to inactivate not only JNK-l and p38, but all
members of the MAPK family as well (37, 44) due to its broad substrate
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specificity. Secondly, heparin may block the activity ofthe pathway at an
upstream point by inactivating an MKK4 homolog. It is clear that heparin binds
and is actively metabolized by endothelial cells and that this binding can prevent
the conversion of a nonthrombogenic phenotype to a thrombogenic one. At this
time, scientific literature contains no obvious answers to the question ofheparin's
action in vascular endothelial cells. However, soon after the pathways studied in·
this work were scrutinized carefully, it was determined that the cell must have a
mechanism through which to modify or shut off its response to mitogenic
stimulation and stress. Several members of a family of phosphatases were found
to have an affinity for SAPK in varying degrees, and their localization in the cell
suggests the compartmentalized control of signal transduction. Heparin treatment
of endothelial cells upregulates the expression ofphosphatases which modify the
activation of SAPKs in vivo. There are several phosphatases with specificity for
constituents of the SAPK pathway, although most have some ability to affect
both stress and mitogenic outcomes. Dual specificity phosphatases, like the ones
that regulate growth and stress pathways, undergo powerful regulated expression
in response to extracellular stimuli (45).
Characterized in 1993, MAP kinase phosphatase-1(MKP-1) is the best
known and appears to be the dominant dual specificity phosphatase in vascular
smooth muscle cells (VSMCs) (46). Its phosphatase nature was detected in a
mitogen-inducible murine gene, 3CH134, which coded for the signature protein-
tyrosine phosphatase (PTPase) motifVHCXAGXXR(S/T)G (47) ofa novel
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family ofphosphatases, where X represents any amino acid. This sequence motif
proved to be essential for phosphatase activity (44), and an essential cysteine
residue is located near the N terminus of the motif (48). A human homolog for
the gene has been identified in CL100 (49). It was found that the removal ofa
phosphate group from either the tyrosine Or threonine residue of a MAPK caused
its inactivation (50). MKP-1 specificity and phosphatase activity was
hypothesized to control unchecked cell growth through the regulation of the
mitogenic outcome of the MAPK pathway. Localization experiments proved
MKP-1 to be exclusively nuclear, suggesting that the inactivation of its substrates
was solely a nuclear event. It was also shown to inhibit cell growth as a G1 cell
cycle inhibitor and constitutive expression proved to repress DNA synthesis (51).
Constitutive MKP-1 expression was also found to inhibitjun kinase activity (52).
A great deal of controversy exists concerning the specificity of MKP-1
to,:"ards MAPKs and SAPKs. The phosphatase has a high degree of substrate
specificity for some MAPKs (47), although it has been shown to inactivate the
p38 and JNK equally (53), and p38 preferentially over ERK2, a MAPK (49). It
has also been shown that the cell needs to produce thirty times more MKP-1 to'
inactivate ERK2 than either JNK known at the time (44). Inhibition ofMKP-1
through the addition of antisense oligonucleotides to the cell system caused
prolonged activation of ERIG and ERK2, despite the evidence that these
substrates are not the enzyme's preferred target (47) These data suggest that
MKP-1 is not alone in inactivatingSAPKs and MAPKs. Furthermore, its broad
11
..
substrate specificity suggests crosstalk between the MAPK and SAPK pathways,
which is supported by recently observed growth attenuation following SAPK
activation. This is most likely because the activation of the SAPK pathway
results in MKP-1 expression (54).
Interestingly, MKP-1 has been shown not only to regulate the activation of
MAPKs and SAPKs, but also its own production through a negative feedback
mechanism (49), demonstrating an additional level of regulation of the SAPK
pathway. This may serve to resensitize cells to subsequent extracellular stimuli.
MKP-1 may also reduce the expression of not only itself, but other dual-
specificity phosphatases as well (49). However, activation of the MAPK
pathway through RaflMEK/ERK has proven insufficient to force the expression
ofMKP-l. Other factors, such as Ca2+, are needed to mimic the production levels
of the phosphatase seen with growth factors. Barring Ca2+-dependent expression
ofMKP-1 causes the sustained activation ofERK. This suggests MKP-1 is an
intersection for crosstalk between several signal transduction schemes, including
the ERK pathway (55).
Because certain MAPKs can be inactivated in the cell in the absence of
MKP-1 (49), it was logical to search for othercandidates with phosphatase
activity to explain this phenomenon. MKP-2 was discovered and characterized in
1996. It was isolated by virtue of the structural homology of its catalytic regions
to MKP-1 and another phosphatase, PAC-I. The gene coding for the protein,
. als·o mown as hVH-2, alsocontains a large 3'-untranslated region of 3 to 6
12
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kilobases which may serve to regulate transcriptional stability (56). The MKP-2
gene was found and isolated from a human mitogen-activated T-cell DNA
library. MKP-2 is not expressed following stimulation of growth or stress
pathways in human fibroblasts, and has been shown to have little or no affinity
for p38, but detectable activity toward JNK-2. Its expression can be forced in vivo
with the addition ofphorbol12-myrisate 13-acetate (PMA), a phorbol ester tumor
promoter (53). This suggests the phosphatases' possible relationship with human
immune response and adhesion molecule expression, particularly in the plaque-
forming phase of heart disease.
Cloned in 1996, the novel gene product MKP-3 displays a localization,
substrate specification, and regulated expression distinct from the other members
of its gene family. MKP-3 contains only 36 percent identity to MKP-1. It does,
however, display great homology to the cell cycle regulator Cdc25, which is also
a phosphatase, in two N-terminal CH2 domains. These 'domains are shared by all
known members of this gene family. Most importantly, MKP-3 is localized in
the cytosol of the cell, the first phosphatase to demonstrate extra-nuclear
restriction. This suggests that MKP-3 blocks nuclear translocation of activated
kinases (57).
MKP-4 exhibits 57 percent identity to MKP-3, and unsurprisingly displays
two N-terminal CH2 domains similar to Cdc25. Its eDNA clone is predicted to
encode a protein of 41.8 Kdal, and an X-linked human homolog has been
- -
identified as Xq28. MKP-4.is present in small quantities in both the nucleus and
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the cytoplasm in lO-20 percent of cells. MKP-4 targets equally the SAPKs, and
has aslightly higher affinity for ERKl and ERK2 (46).
Another dual-specificity phosphatase, M3/6, demonstrates a highly
specific preference for p38 and JNK, and inactivity versus MAPKs. Like MKP-
3, M3/6 is a cytosolic factor. The gene coding for M3/6 contains a complex
trinucleotide repeat, which codes for multiple serine and glycine repeats in the C-
terminal third of the protein (58).
In this thesis we report the downregulation of activated p38 in endothelial
cells through the addition of heparin. Our lab has definitive evidence that the
deactivation of MAPKs in a VSMC system is attributed to expression of MKP-l
(Isleib, unpublished results). Also, recent experiments in our lab indicate the
increased deactivation ofp38 with a concomitant increase in MKP-l expression
in endothelial cells (Moore, unpublished results). We approached the question of
heparin's downregulation of the SAPK pathway in two parts. First, the maximal
activation ofp38 and JNK-l was studied, and then the change in SAPK
phosphorylation upon addition of heparin to activated cells was quantified.
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MATERIALS AND METHODS
Materials
Calfpulmonary artery endothelial cells (CPAEs) and capillary bovine
vascular endothelial cells (EJGs) were obtained commercially through American
Type Culture Collection (Manassas, VA). Cell culture and electrophoresis
solutions were made up according to supplier's protocols. Denaturing lysate
consisted of 1% SDS, 10 mM Tris Cl (pH = 7.4), and 1mM NaV04• 2X sample
buffer was made up of 4% SDS, 20% glycerol, 0.125 M Tris (pH = 6.8), and 10%
2-mercaptoethanol. lOX TBS consisted of 60.6 g Tris base and 87.7 g NaCl
diluted to 1 L with deionized water (pH =7.5). Blotto consisted of 50 g Carnation
Non-fat dry milk in 1800 mL ofTris Buffered Saline (TBS), and 100 ilL of 4%
sodium azide, and TBST was composed of0.1 % Tween-20 in IX TBS.
Developing solution for Western blots was made up of 50 III of 5-bromo-4-
chloro-3-indolyl phosphate and 500 III ofnitro blue tetrazolium in 50 ml of IX
alkaline phosphatase buffer. IX alkaline phosphatase buffer was made up of 50
ml10X Alkaline phosphatase buffer mixed with 450 m1 deionized water. lOX
alkaline phosphatase buffer consisted of 121.2 g Tris base, 5804 g NaCl, and 10.1
g MgCh·6HzO. EDTA solution was comprised of 1 g glucose, .025 g Naz-EDTA,
and 100 mL lOX phosphate-buffered saline (PBS) diluted to 1 L with deionized
15
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water. lOX PBS consisted of 2 g KCl, 2 g KHZP04, and 11.5 g NazHP04 diluted
to 1 L with deionized water.
Cell Culture
CPAEs were cultured in minimal essential media (MEM) (Sigma,·St.
Louis, MO) with a total volume media solution of 450 ml of containing 10 ml of
0.2 M glutamine in deionized water, 5 m1 ofpenicillin-streptomycin (penicillin 1
units/mL, streptomycin 1 ~g/mL) (Sigma, St. Louis, MO), and 50 m1 of heat-
inactivated fetal bovine serum (Sigma, St. Louis, MO, and Atlanta Biologicals,
Atlanta, GA). Media was changed every other day in non-confluent plates, and
every seven days in confluent plates. Cells were sometimes allowed to become
cOJ?fluent on 100 mm plates, and were sometimes harvested before confluence
was achieved. Transfer on to new plates was achieved through the addition of 5
mL of EDTA solution. 5 mL of trypsin was added, and plates were incubated at
37° C for five minutes. Plate contents were centrifuged for five minutes with 5
mL of MEM media, and were resuspended in media. The suspension was equally
divided among plates precoated with a 0.5% solution ofgelatin.
Experimental Protocols
Plates of cells were treated with TNF-a (Sigma, St. Louis, MO, and R&D
Systems, Minneapolis, MN) and incubated for 5 to 45 minutes before harvesting.
Addition ofTNF-a to 100 mm plates varied from 25-50 ~L for a final
concentration of2.5-5 ng/mL of media. Other plates were treated with 100 ~l of
16
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a fresh O.Olg heparin/l ml deionized water solution for ten minutes, followed by
treatment with TNF-a before harvesting. Cells were harvested with 1mL ofhot
denaturing lysate solution. Harvested cell samples were sometimes stored in the
freezer until SDS-PAGE could be performed. This cell solution was mixed with
2X sample buffer in a 1: 1 ratio. Samples were then run on a 10% SDS-
polyacrylamide gel using Laemmli buffer system (59) and transferred onto
nitrocellulose.
Detection ofProteins ofInterest
1) Detection ofp38
Nitrocellulose blots were incubated for two hours at room temperature or
overnight in the 37° F cold room with Blotto to block non-specific antibody
binding. Blots underwent three 10-minute washes in TBST and were placed into
a p38 primary antibody (Santa Cruz Biologicals, Santa Cruz, CA #sc-535)
dilution of 1:500 (100 ilL antibody in 50 mL of Blotto) for two hours at room
temperature or overnight in the cold room. Excess primary antibody was
removed with three 10-minute washes in TBST. Incubation with donkey anti-
rabbit biotin confiigate secondary antibody (Jackson ImmunoResearch Labs,
West Grove, PA) in a 1:5000 dilution (10 ilL antibody in 50 mL ofTBST)
followed a similar incubation to the primary antibody, and then blots were again
placed in three lO-minutes washes in TBST. Blots were incubated in a 1:300,000
solution of ExtrAvidin alkaline phosphatase (3 ilL ExtrAvidin in 50 mL of
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TBST) for two hours at room temperature or overnight in the cold room.
ExtrAvidin was obtained from Sigma in St. Louis, MO. Blots were then washed
twice for 10 minutes in TBST, and again in an additionallO-minute wash in IX
alkaline phosphatase buffer. Developing solution with NBT and BCIP was then
added to visualize the appropriate protein bands, and protein levels were
quantified using the densitometer. Some experiments were run with secondary
antibody only to identify bands of interest.
2) Detection ofphospho-p38
Blots were blocked as in p38 protocol. Blots underwent three lO-minute
washes in TBST and were placed into phospho-p38 primary antibody (New
England Biolabs, Beverly, MA) in a I:500 dilution (consisting of40 /-lL of
antibody, 40 /-lL of 25% Tween 20, 36 mL of deionized water, 2 g ofbovine
serum albumin (BSA), and 4 mL of lOX TBS) for two hours at room temperature
or overnight in the 37° F cold room. Excess primary antibody was washed away
with three to-minute washes in TBST. Incubation with donkey anti-rabbit biotin
conjugate secondary antibody (Jackson ImmunoResearch, West Grove, PA)
followed a similar incubation to the primary antibody, and then blots were again
placed in three 10-minutes washes in TBST. The remaining steps in blot
development were identical to those of the above procedure for p38, although
phospho-p38 blots were compared to p38total protein blots for band localization.
3) Detection ofJNK-l
- --- -- -----------------
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Blots were blocked as in p38 protocol. Blots underwent three 10-minute
washes in TBST and were placed into JNK-l primary antibody (Santa Cruz
Biologicals, Santa Cruz, CA, #sc-57l) in a 1:500 dilution (100 j.lL antibody in 50
mL Blotto) for two hours at room temperature or overnight in the cold room. The
.remaining steps in blot development were identical to those of the above
procedure for p38.
4) Detection ojp-JNK
Blots were blocked as in p38 protocol. Blots underwent three lO-minute
washes in TBST and were placed into p-JNK primary antibody (Santa Cruz
Biologicals, Santa Cruz, CA) in a 1:500 dilution (100 j.lL antibody in 50 mL
TBST) for two hours at room temperature or overnight in the 37° F cold room.
Excess primary antibody was removed with three 10-minute washes in TBST.
Incubation with goat anti-mouse secondary antibody (Jackson ImmunoResearch,
West Grove, PA) in a 1:10,000 dilution (5 j.lL antibody in 50 mL ofTBST)
followed a similar incubation to the primary antibody, and then blots were again
placed in three 10-minutes washes in TBST. The remaining steps in blot
development were identical to those ofthe above procedure for p38, although
blots were compared to JNK- t total protein blots for band localization.
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Results
Activation ofp38 and JNK-l with TNF-ain Bovine Endothelial Cells
In order to determine heparin's effect on the SAPK pathway in endothelial
cells, the pathway must first be activated. Candidate molecul~s suspected to set
the SAPK pathway in motion include interleukin-IB (IL-l ~), lipopolysaccharide
(LPS), histamine, and tumor necrosis factor-a (TNF-a). All of these molecules
were tested for their ability to induce phosphorylation ofp38 and JNK-l in vitro
in confluent endothelial cells. LPS (see Figure.l) and IL-l ~ produced little or no
consistent activation of either SAPK. Treatment of confluent cells with hIstamine
resulted in weak activation of both p38 and JNK-1, although the phosphorylation
of JNK-l was much more consistent in both cell types (see Figure 2). TNF-a
produced the most consistent and strongest activation over short time courses (see
Fig. 3).
A survey of recent literature reveals TNF-a to be a powerful and
consistent activator of the stress pathway in bovine cells, a conclusion borne out
by this study. Time courSe experiments with TNF-a were performed on bovine
endothelial cells to determine the incubation time which produced maximal
activation. Using confluent 100 mm plates of cells we assayed for activation of
the stress pathway by immunoblotting. Using standard molecular weight rainbow
markers and comparison to p38 total protein blots, we determined that the
maximal activation ofp38 was achieved through a ten minute incubation of the
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stressor with confluent cells (see Figure 3, panel A). Although activation of the
enzyme is clearly seen by ten minutes of incubation, no change in total protein
was seen over the course of the experiment (see Figure 3, panel B). Quantitative
analysis by densitometry of the phospho-38 can be seen in panel C of Figure 3.
Activation of p38 was also seen most strongly at ten minute incubations of 50 ilL
of TNF-a with confluent bovine EJGs (Figure 4, panel A). Again, there was no
change in total protein in EJGs (Figure 4, panel B).
Total protein blots in both cell types reveal p38 to be the dominant SAPK
enzyme in these cell lines. This may account for the faint banding in many blots
stained for p-JNK, as the inactivated protein seems to be expressed in much lower
quantities than p38. Although phosphorylation of JNK-l was achieved in bovine
CPAEs, its activation proved less definitive than that of p38. The enzyme
appears to be maximally activated also through a ten minute incubation with 50
ilL ofTNF-a with confluent cells (Figure 5). Total JNK-l protein remains
constant over the time course (data not shown).
Heparin downregulates activated p38
Experiments to demonstrate heparin's ability to decrease the stress
response at the SAPK level were performed largely with TNF-a due to its greater
capacity for activation and its reliability. These studies revealed a new variable
in these experiments which demanded consideration. Despite the demonstrated
.effect of the addition of heparin ten minutes before incubation with stressors
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(Gilotti, unpublished results), blots probing for activated p38 in confluent cells
showed little or no downregulation of the stress response in CPAEs (Figure 6).
Plates which were incubated for ten minutes with various heparin concentrations
and then probed for the presence of the immediate early gene product MKP-1
demonstrated the unexpected constitutive expression of the phosphatase in all
lanes, including controls without heparin (Moore, 1999, unpublished results).
Figure 7 and the accompanying data analysis of the blot (Graph 2) make this
finding evident. Experiments in which cells were only 70 to 85 percent
confluent, however, show that heparin induced changes in SAPK activity. Figure
8, panel A, and its accompanying data analysis (panel B) demonstrate heparin's
modulation ofp38 activation by TNF-a over a short (5 to 15 minute) time course.
No evidence of constitutive MKP-1 expression was found in the heparin
concentration experiments with non-confluent CPAEs, however (Figure 9, panels
A and B). Instead, there is a dose-dependent relationship between heparin
concentration af.ld MKP-1 expression. No evidence of downregulation of
activated JNK-1, however, was observed. This may be because the total amount
of JNK-1 protein is very limited in these cell lines (data not shown).
Finally, the addition of only half as much TNF-a in non-confluent cells seemed
to produce at least as much activation ofp38 as in confluent plates (Figure 10,
panels A and B).
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.,.I Discussion
This study was designed to discern heparin's effects in endothelial cells on.
the stress pathway which modulates the body's response to the arterial events
which lead to atherosclerosis.
The differentiation between heparin's effects in confluent and non-
confluent plates of cells makes clear several points. First, the suggestion of
redundancy between the MAPK pathway, with its mitogenic outcome, and the
signal transduction of an extracellular stress message is valid. Constitutive
expression of MKP-l in confluent cells demonstrates one of the ways in which
confluent cells suppress unnecessary growth, and by doing so, dampen the
"resensitization" process discussed by Franklin (49). This resensitization may
modulate overall levels of SAPKs as well. A consideration of the circumstances
under which atherosclerosis begins suggests that a confluent monolayer of cells
may not be the best model of the endothelial portion of the human artery with
which to study the disease in vitro. A saturation of focal contacts causes cells to
shut off the MAPKpathway, and also curb signal transduction in the SAPK
pathway. Non-confluent cells, however, seem to show both stronger activation of
p38 in particular; and may have different levels of SAPK enzymes. Non-
confluent cells also reveal heparin's effects on p38 activation. The lack of
downregulation at the 15 minute time point in Figure 8 likely depicts a loading .
inconsistency, as heparin's effects have usually been found to extend beyond ten·
.~
minutes after addition. Visual inspection suggests that the 15 minute time point
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with heparin had decreased despite densitometry data suggesting it had stayed
activated. These results should be confirmed. Further experimentation must also
assure that proteins of interest compared between non-confluent and confluent
cells are considered in proper context and proportion. Also, a study of SAPK
pathway activators that proved unsuccessful in this work, like IL-l ~ and LPS,
may prove fruitful in a non-confluent system, as non-confluent cells
demonstrated activation at a lower concentration of stressor.
Heparin's failure to clearly bl,?ck the activation of JNK-l in endothelial
cells may have several root causes. Most obviously, JNK-l exists at a low level in
an inactivated form in confluent endothelial cells, as evidence by the light or
absent total protein bands seen in many of our JNK-l experiments. Non-
confluent cells may contain too little of the enzyme to properly assay its decrease
in activity upon heparin treatment. This situation may be remedied by different
methods of sample harvesting to increase JNK-1 concentration during
immunoblotting. Also, SAPKs contain no nuclear localization signal, and the
proteins most probably enter the nucleus through the use of chaperone proteins.
It is possible that endotheliaICens fail to upregulate the chaperone proteins
needed to move p-JNK into the nucleus, where the enzyme could be
dephosphorylated by MKP-l, a nuclear phosphatase. Although JNK-l is a known
substrate of MKP-l, it may be the preferred substrate of another phosphatase,
such as M3/6, which specifically deactivates SAPKs. If this is true, then this
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phosphatase is apparently not upregulated in response to heparin treatment, as is
MKP-l.
JNK-l may also be dephosphorylated in the cytosol by a non-nuclear
phosphatase, and its possible that sufficient quantities of p-JNK never translocate
into the nucleus to become MKP-l 's substrate. Another aspect of JNK-1's
failure to downregulate upon heparin treatment may concern a downstream
constituent oftbe SAPK pathway which is affected by MKP-l, and not the SAPK
itself. In support of this theory, heparin treatment blocks many of the
physiological endpoints of atherosclerosis; such as cell adhesion molecule
'.
,expression, that are known to be associated with JNK-l activation. Further
experimentation may shed light on JNK-l 's failure to downregulate in this study,
and should include an immunofluorescence study to determine the localization of
p38 and JNK-l upon their activation. Further work will be needed to determine
which steps of the stress pathway are altered in confluent cells.
Heart disease remains one the western world's leading killers. Heparin or,
more likely, its analogs may prove to be key to developing a new treatment
protocol for atherosclerosis. Heparin's ability to downregulate the activation of
some SAPKs in response to the minor injury that marks the genesis of the disease
is separate from its anti-coagulant properties. With further study, this aspect of
heparin's action could be exploited for medical use.
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Conclusions
- CPAEs and EJGs are stressed by tumor necrosis factor-a, and to a lesser
extent, by histamine, as measured by levels ofphospho-p38 and p-JNK by
immunoblotting. Confluent endothelial cells appear less stressed than sub-
confluent cells, most likely due to the constitutive presence of the dominant
MAPK phosphatase, MKP-l. ~onfluent endothelial cells resist heparin's effects
on SAPK activity levels. However, our data suggests that sub-confluent cells
respond to heparin with lower active phospho-p38 levels in TNF-treated cells,
demonstrating a modulation of the pathway that leads to atherosclerosis. While
JNK-l appears not to respond to heparin treatment, levels of JNK in sub-
confluent cells may be too low for accurate determination of heparin effects.
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CPAES with LPS stained for phospho-p38
· Control
Figure 1.
15 Minutes 30 Minutes 45 Minutes
LPS Fails to Activate p38 in Bovine CPAEs
Bovine CPAEs were incubated with 50 JlL lipopolysaccharide (LPS)
(final concentration of 5 Jlg/ mL) for 0 to 45 minutes. The control lane
contains no LPS. The blot was stained with phospho-p38 antibody.
No activation was seen at any time point. The arrow indicates the region
of the phospho-p38 protein.
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CPAEs with histamine stained for p-JNK
')
Control
Figure 2.
15 Minutes 30 Minutes 45 Minutes
Histamine activates JNK-l in CPAEs
Bovine CPAEs were incubated with 50 ~L stock histamine (0.001841
mg/mL :water) for a final concentration of9.2 ng/mL for 0 to 45 minutes.
Cell samples were harvested and run on 10% SDS-PAGE, and the blot
was stained with p-JNK antibody.
Slight activation can be seen at the 15,30, and 45 minute time points,
with 30 minutes staining most heavily.
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A. CPAEs with TNF-a stained for phospho-p38
Control 5 Mins. 10 Mins.. 15 Mins. 20 Mins.
B. CPAEs with TNF-a stained for total p38
Control 5 Mins. 10 Mins. 15 Mins. 20 Mins.
Figure 3.
TNF-a activates p38 in bovine CPAEs
Bovine CPAEs were incubated with 50 JlL TNF-a (final concentration
of 5 ng/mL) for 0 to 20 minutes. Cell samples were harvested and run on
a 10% SDS-PAGE, and the blot was stained with phospho-p38 antibody.
Activation can clearly be seen in the 5, 10, and 15 minute samples, and it
peaks at the 10 minute ti~e point.
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C. Data Arialysis:
Graph 1. Phospho-p38 levels ofCPAEs with TNF-a.
Bovine CPAEs with TNF
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A. EJGs with TNF-a stained for phospho-p38
Control 10 Mins. 20 Mins. 30 Mins.
B. EJGs with TNF-a stained for total p38 protein
Control
Figure 4.
10 Mins. 20 Mins. 30 Mins.
TNF-a activates p38 in bovine EJGs
Bovine EJGs were incubated with 50 JiL of TNF-a (fmal concentration
of 5 ng/mL) for 0 to 10 minutes. Cell samples were harvested and run on
a 10% SDS-PAGE. The blot was stained with.phospho-p38 antibody.
Activation' can clearly be seen in the 10,20, and 30 minute samples,
peaking in between the control and 20 minute time points.
Total protein remains constant throughout the time course.
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CPAEs with TNF-a stained" for p~JNK r
)
Control
Figure 5.
15 Minutes 30 Minutes .45 Minutes
TNF-a activates JNK-l in bovine CPAEs
Bovine CPAEs were incubated with 50 J.1L ofTNF-a (final
concentration of 5 ng/mL) for 0- to 45 minutes. The control lane
contains no TNF-a. The blot was stained with p-JNK antibody.
Activation can be seen in the 15, 30, and 45 minute samples. It peaks in
the 30 minute lane.
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A. CPAEs with TNF-aonly stained for phospho-p38
,.j
B. CPAEs with heparin and TNF-a stained for phospho-p38
Control
Figure 6.
5 Mins. 10 Mins. 15 Mins. 20 Mins.
Heparin fails to block p38 activation by
TNF-a in confluent'bovine CPAEs
" .
Bovine CPAEs were treated with 100 J-LL of fresh heparin (0.10 mg/rnL
deionized water) for a final concentration of 100 Ilg/rnL for 10 minutes,
and then were incubated with 50 J-LL of'TNF-a (final concentration of 5
ng/rnL) for ato 20 minutes. Cell samples were harvested and run on a
10% SDS-PAGE. The blot was stained with phospho-p38 antibody~
Heparin does not obviously suppress p38 activation at any point.
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A. CPAEs with heparin stained for MKP-l
..
Control
Figure 7.
10 min 20 min 30min . 40 min
MKP-llevels are constant despite
incubation with heparin from 0-40
minutes in confluent bovine CPAEs.
4.0.,.------------------,
3.5
3.0
ll)§ 2.5
'€ 2.0
o
f/l
~ 1.5
1.0
0.5
0.0
Control 10 20
Time (minutes)
30 40
Bovine CPAEs were treated with 100 ilL ofheparin (0.01 mg heparin/mL of .
deionized water) for a fina1·concentration of 100 Ilg/mL. Cells samples were
harvested and run on a 10% SDS-PAGE. Blots were stained with MKP-1
antibody. Note MKP-1 appears in the untreated contro1~ and at similar levels
throughout each time point.
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A. CPAEs with TNF-u and heparin
..
Con 5 Min 10 Min. 15 Min.
TNF-a only
Figure 8.
Hep 5 Mins. 10 Min 15 Min.
Heparin and TNF-a
Heparin downregulates activation of p38
in non.-confluent bovine CPAEs
Four plates ofnon-confluent bovine CPAEs were incubated with 25 ~L of
TNF-a (final concentration of2.5 ng/mL) for 0 to 15 minutes; four others
were treated with 100 ~L of fresh heparin (0.01 mg heparin/mL of
deionized water) for a final concentration of 100.~g/mL for 10 minutes
-and were then incubated with 25 ~L ofTNF-a (final concentration of2.5
ng/mL) for 0 to 15 minutes. Cell samples were harvested and run on a
10% SDS-PAGE. The blot was stained with phospho-p38 antibody.
Downregulation ofp38 activation can be seen at the 5 and 10 minute
.. ~
tIme pomts..
Panel B-shows the results of densitometry analysis of the above blot.
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B.Data analysis by densitometry
. Heparin downregulates p38 activation in CPAEs
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A. Bovine CPAEs with heparin stained for MKP-l
Control 50 Ilg/ml 75 Ilg/ml lOOllg/ml 150 Ilg/ml 200 Ilg/ml
Figure 9.
MKP-llevels rise in~a dose-dependent
manner when non-confluent CPAEs are
incubated with different concentrations of
heparin
Non-confluent bovine CPAEs were incubated with varying concentrations of
heparin from 0 to 200 Ilg/mL. Cell samples were harvested and run on a 10%
SDS-PAGE, and the blot was treated with MKP-l antibody. Note the rise in
MKP-l expression which peaks at 100 Ilg/mL.
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B. Data analysis by densitometry
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A. Confluent CPAEs ,treated with 50 J.lL of TNF-"a and stained for
hospho-p38
. .' ': '-'~:/
Control 5 Mins. 10 Mins. 15 Mins. .20 Mins.
B. Non-confluent CPAEs treated with 25 J.lL ofTNF-o' and stained
for P~?~l?ho-p3 8
Control 5 Mins. 10 Mins. 15 Mins.
Figure 10.
Non-confluent bovine CPAEs stress
more easily than confluent cells
Bovine CPAEs were incubated with either 50 J.lL for a final
concentration of 5 ng/mL (in panel A, confluent cells) or 25 J.lL for a
final concentration 2.5 ng/mL (in panel B, non-confluent cells) of
TNF-a over a short time course. Cell samples were harvested and
run on a 10% SDS-PAGE. The blots were stained with phospho-p38
antibody.
Panel B demonstrates that non-confluent cells are more highly
activated by TNF-o' than confluent cells upon the addition ofhalf as
much stressor.
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